Search the Newsreel

Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat

Bristol Myers Squibb has once again delayed the phase 3 data readout for its Alzheimer's disease psychosis drug, Cobenfy, moving the expected arrival of data to early 2027 due to slower patient enrollment and relapse event accrual. Despite this setback and a muted launch …

Bristol Myers Squibb erhöht die Prognose für 2026 nach besser als erwarteten Ergebnissen im zweiten Quartal.

Bristol Myers Squibb raises 2026 forecast after Q2 earnings beat

Bristol Myers Squibb has increased its full-year revenue and earnings forecast for 2026 following better-than-expected second-quarter results. Strong sales of its blood thinner Eliquis, along with newer drugs like Camzyos and Reblozyl, drove revenue to $12.97 billion, surpassing analyst estimates. The company now expects …

Bristol Myers Squibb Reports Second Quarter Financial Results for 2026

Bristol Myers Squibb reported its second-quarter 2026 financial results, which can be viewed on the company's Investor Relations website. The biopharmaceutical company hosted a conference call and live audio webcast for analysts and investors to discuss these results. A replay of the webcast will …

Bristol-Myers stock gains after Q2 2026 beat (BMY:NYSE)

Bristol-Myers Squibb (BMY) raised its full-year outlook after reporting better-than-expected Q2 2026 financials, driven by strong sales of its cancer therapies. The company reported approximately $13.0B in revenue, a ~6% YoY growth. The updated guidance for full-year revenue is $49.0B–$50.0B and adjusted EPS is …

Bristol Myers Raises Guidance After Record-Breaking Sales

Bristol Myers Squibb Co. increased its sales and profit outlook for 2026 following better-than-expected second-quarter demand for its drugs, particularly newer treatments for heart conditions and cancer. The company now expects full-year sales between $49 billion and $50 billion, up from an earlier forecast, …

Bristol-Myers Squibb superaron 0.43$ las previsiones de BPA en el segundo trimestre del año

BRISTOL-MYERS SQUIBB ($BMY) Releases Q2 2026 Earnings

Bristol Myers Lifts Outlook as Profit, Revenue Rise

Bristol Myers Squibb raised its full-year earnings and revenue outlook after reporting increased profit and revenue in the latest quarter. The biopharmaceutical company now forecasts earnings of $6.75 to $7 per share and revenue of $49 billion to $50 billion, an increase from its …

Bristol Myers raises 2026 forecast as Eliquis, newer medicines power results

Bristol Myers Squibb significantly raised its full-year revenue and profit forecasts for 2026 after reporting strong second-quarter results, driven by robust sales of blood thinner Eliquis and newer drugs like Camzyos and Reblozyl. The company's strategy to counter sales declines from older medicines facing …

Bristow Group Inc (VTOL) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Bristow Group Inc (VTOL), noting its current valuation score and ranking within the Passenger Transportation Services industry. It highlights the company's P/E ratio and mentions that relevant data for P/B, P/S, and P/CF ratios have not yet …

Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales

Bristol-Myers Squibb (NYSE:BMY) reported strong Q2 CY2026 financial results, surpassing analyst expectations for both revenue and non-GAAP profit. The company's revenue grew 5.7% year-on-year to $12.97 billion, and its full-year revenue guidance of $49.5 billion also exceeded estimates. Despite strong quarterly performance, the company …

Edgestream Partners L.P. Buys Shares of 154,427 Bristol Myers Squibb Company $BMY

Edgestream Partners L.P. has acquired a new position in Bristol Myers Squibb Company (NYSE:BMY), purchasing 154,427 shares valued at approximately $9.366 million during the first quarter. This increased institutional ownership in the biopharmaceutical company, with other major investors like Vanguard Group Inc., State Street …

Bristow Group Inc Today's Market Trends | VTOL Stock Real-Time Quotes, Trading Strategies & Related Analysis | TradingKey

Bristow Group Inc. (VTOL) is a provider of vertical flight solutions, primarily offering aviation services to offshore energy companies and government entities. The company's fundamentals are strong with high growth potential, and its stock is considered fairly valued. Analysts have rated VTOL as "Buy" …

Informe de resultados: Bristol Myers supera las estimaciones del segundo trimestre de 2026

Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates

Bristol Myers Squibb Lifts Full-Year Guidance After Strong Second-Quarter Earnings Beat

Bristol Myers Squibb hebt Prognose an nach Wachstumsschub - Aktie steigt vorbörslich

¿Han cambiado la presentación conjunta de la solicitud de Opdivo y la expansión de la I+D impulsada por la IA el enfoque de inversión de Bristol-Myers Squibb (BMY)?

Bristow Group Inc (VTOL) Stock Score & Comprehensive Stock Analysis

This article provides a comprehensive stock analysis of Bristow Group Inc (VTOL) by TradingKey. It highlights that the company's fundamentals are healthy, growth potential is high, and valuation is considered fairly valued. Analyst ratings are generally positive, with a "Buy" consensus and a target …

Enterprise value to EBITDA forward of Bristow Group, Inc. – BOATS:VTOL

This article provides the enterprise value to EBITDA forward for Bristow Group, Inc. (VTOL). It appears to be a financial data snippet from a platform like TradingView, with no additional textual analysis or details provided.

Bank Syariah Indonesia Number of Employees 2026 | Employee Count & Headcount Data

The Manufacturers Life Insurance Company Raises Stock Holdings in Bristol Myers Squibb Company $BMY

The Manufacturers Life Insurance Company increased its holdings in Bristol Myers Squibb (NYSE:BMY) by 15.8% in the first quarter, adding 241,405 shares to reach a total value of approximately $107.1 million. Institutional investors now own 76.41% of BMY, while analyst sentiment remains mixed with …

Opal Capital LLC Buys Shares of 22,664 Bristol Myers Squibb Company $BMY

Opal Capital LLC recently acquired 22,664 shares of Bristol Myers Squibb (NYSE:BMY) in the first quarter, valued at approximately $1,375,000. Other institutional investors have also adjusted their holdings in the biopharmaceutical company, which has seen its stock perform within a 12-month range of $42.52 …

BMY|Bristol-Myers Squibb Co|Price:63.635|Chg%:+1.075

This article provides a comprehensive overview of Bristol-Myers Squibb Co (BMY) stock, including real-time quotes, key financial figures, performance trends, and analyst ratings. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the pharmaceuticals industry. The stock is currently rated …

California State Teachers Retirement System Has $201.19 Million Stake in Bristol Myers Squibb Company $BMY

The California State Teachers Retirement System reduced its stake in Bristol Myers Squibb Company (BMY) by 2.3% in the first quarter, now owning 3,317,201 shares valued at $201.19 million. Other institutional investors have also adjusted their positions in the biopharmaceutical company. Analysts currently rate …

Bristol Myers Squibb Company $BMY Shares Sold by Empowered Funds LLC

Empowered Funds LLC significantly reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 38.0% during the first quarter, selling 210,880 shares and leaving them with 344,513 shares valued at over $20 million. Other institutional investors like Swiss RE Ltd., Darwin Wealth Management LLC, …

Bristol Myers Squibb Hopes to Boost Drug Trials with NVIDIA Supercomputer

Bristol Myers Squibb (BMS) is set to become the first life sciences company to acquire NVIDIA's latest generation supercomputer, the NVIDIA DGX SuperPOD with AIDGX Vera Rubin NVL72 systems. This move deepens a three-year partnership between the two companies, aiming to accelerate drug discovery …

Bristol Myers Squibb (BMY) Stock Still Looks Cheap After Fresh AI Drug Discovery News

Bristol Myers Squibb (BMY) has seen a 42.2% return over the past year, with a Discounted Cash Flow (DCF) model suggesting its intrinsic value is significantly higher than its current share price, implying it's undervalued by 48.1%. The company's expansion into AI-driven drug discovery …

Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q2 Results Tomorrow

Bristol-Myers Squibb (BMY) is set to report its Q2 earnings this Thursday before market open. The company previously beat revenue expectations but slightly missed full-year EPS guidance. Analysts generally anticipate a 6.3% year-over-year revenue decline this quarter, while investor sentiment for the pharmaceutical sector …

Bristow Group will publish Q2 results Aug. 4 before its Aug. 5 call

Bristow Group (NYSE: VTOL) announced it will release its second-quarter 2026 financial results after market close on Tuesday, August 4, 2026. A conference call to discuss these results is scheduled for Wednesday, August 5, 2026, at 10:00 a.m. ET. Investors can access a live …

Bristow Group Announces Second Quarter 2026 Earnings Call

Bristow Group (NYSE: VTOL) announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 8, 2025, after market close. The company will also host an investor conference call and webcast on Friday, August 9, 2025, at …

New Iza-bren Approvals Underscore China's Rising Role In Bispecific ADCs

New approvals for Biokin’s Iza-bren, a first-in-class EGFRxHER3 bispecific ADC, for advanced nasopharyngeal carcinoma and recurrent or metastatic esophageal squamous cell carcinoma, highlight China's growing influence in this field. Biokin aims for global commercialization, leveraging its first-mover advantage and partnership with Bristol Myers Squibb. …

Lazard Asset Management LLC Raises Stake in Bristol Myers Squibb Company $BMY

Lazard Asset Management LLC increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 23.7% in the first quarter, now owning 1,924,036 shares valued at $116.69 million. Other institutional investors like Vanguard Group Inc., State Street Corp, and Geode Capital Management LLC also significantly …

Bristow Group (VTOL) to Release Earnings on Tuesday

Bristow Group Inc (VTOL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Bristow Group Inc (VTOL), focusing on its regional contributions. The data indicates that the UK is the largest revenue contributor, followed by International, Norway, US, and Nigeria. However, detailed financials for business segments and current fiscal years …